Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Niacinamide
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyrroles
  • Sirolimus

abstract

  • In patients with mRCC and progression on sunitinib, second-line temsirolimus did not demonstrate a PFS advantage compared with sorafenib. The longer OS observed with sorafenib suggests sequenced VEGFR inhibition may benefit patients with mRCC.

publication date

  • March 10, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5569683

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.50.3961

PubMed ID

  • 24297950

Additional Document Info

start page

  • 760

end page

  • 7

volume

  • 32

number

  • 8